Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Leases: 2022-2024

Historic Current Leases for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $7.6 million.

  • Entrada Therapeutics' Current Leases fell 43.78% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 43.78%. This contributed to the annual value of $7.6 million for FY2024, which is 4.43% down from last year.
  • Per Entrada Therapeutics' latest filing, its Current Leases stood at $7.6 million for FY2024, which was down 4.43% from $7.9 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Current Leases ranged from a high of $8.4 million in FY2022 and a low of $7.6 million during FY2024.
  • Its 3-year average for Current Leases is $8.0 million, with a median of $7.9 million in 2023.
  • Data for Entrada Therapeutics' Current Leases shows a maximum YoY dropped of 5.91% (in 2023) over the last 5 years.
  • Over the past 3 years, Entrada Therapeutics' Current Leases (Yearly) stood at $8.4 million in 2022, then decreased by 5.91% to $7.9 million in 2023, then declined by 4.43% to $7.6 million in 2024.